MX351133B - Metodo para tratar osteoporosis. - Google Patents

Metodo para tratar osteoporosis.

Info

Publication number
MX351133B
MX351133B MX2014003027A MX2014003027A MX351133B MX 351133 B MX351133 B MX 351133B MX 2014003027 A MX2014003027 A MX 2014003027A MX 2014003027 A MX2014003027 A MX 2014003027A MX 351133 B MX351133 B MX 351133B
Authority
MX
Mexico
Prior art keywords
treating osteoporosis
osteoporosis
iopropane
dicarboxamide
henyl
Prior art date
Application number
MX2014003027A
Other languages
English (en)
Other versions
MX2014003027A (es
Inventor
T Aftab Dana
Clary Douglas
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2014003027A publication Critical patent/MX2014003027A/es
Publication of MX351133B publication Critical patent/MX351133B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Esta invención se dirige al tratamiento de la ospeoporosis mediante el uso de N-(4-{[6,7- bis (metiloxi) quinolin -4-i]oxi] fenil)-N´-(4-fluorofenil) ciclopropano -1,1- dicarboxamida.
MX2014003027A 2011-09-22 2012-09-20 Metodo para tratar osteoporosis. MX351133B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161538039P 2011-09-22 2011-09-22
PCT/US2012/056281 WO2013043840A1 (en) 2011-09-22 2012-09-20 Method for treating osteoporosis

Publications (2)

Publication Number Publication Date
MX2014003027A MX2014003027A (es) 2014-10-24
MX351133B true MX351133B (es) 2017-10-03

Family

ID=47010756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003027A MX351133B (es) 2011-09-22 2012-09-20 Metodo para tratar osteoporosis.

Country Status (19)

Country Link
US (1) US10166225B2 (es)
EP (2) EP3275443A1 (es)
JP (1) JP6240075B2 (es)
KR (1) KR20140069133A (es)
CN (1) CN103957915A (es)
AR (1) AR087995A1 (es)
AU (1) AU2012312364B2 (es)
BR (1) BR112014006702A2 (es)
CA (1) CA2848512A1 (es)
EA (1) EA201490676A1 (es)
ES (1) ES2639093T3 (es)
GE (1) GEP201606523B (es)
HK (1) HK1201040A1 (es)
IL (1) IL231495B (es)
MX (1) MX351133B (es)
TW (1) TWI564009B (es)
UA (1) UA115866C2 (es)
WO (1) WO2013043840A1 (es)
ZA (1) ZA201401728B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
WO2012044572A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
BR112014006702A2 (pt) 2011-09-22 2017-06-13 Exelixis Inc método para tratar osteoporose
CA2852771C (en) 2011-10-20 2019-11-26 Exelixis, Inc. Process for preparing quinoline derivatives
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
MX366003B (es) 2013-03-15 2019-06-24 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
MX2021001583A (es) 2014-02-14 2023-02-08 Exelixis Inc Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
US10159666B2 (en) 2014-03-17 2018-12-25 Exelixis, Inc. Dosing of cabozantinib formulations
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
CN106715397B (zh) * 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
EP3177311A1 (en) 2014-08-05 2017-06-14 Exelixis, Inc. Drug combinations to treat multiple myeloma
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
MA48776A (fr) 2017-05-26 2020-04-08 Exelixis Inc Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
CR20230287A (es) 2018-01-26 2023-07-26 Exelixis Inc COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358)
US20220152274A1 (en) * 2020-11-19 2022-05-19 University Of Massachusetts Demineralized bone paper

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1401411A2 (en) * 2001-06-29 2004-03-31 AB Science Use of tyrosine kinase inhibitors for treating bone loss
DK2392564T3 (da) 2003-09-26 2014-01-13 Exelixis Inc c-Met-modulatorer og anvendelsesfremgangsmåder
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
JP4572269B2 (ja) * 2004-11-25 2010-11-04 財団法人ヒューマンサイエンス振興財団 癌の骨転移のリスクの予測方法
WO2006108059A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
WO2008044379A1 (fr) * 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
MX2009009243A (es) * 2007-03-02 2009-09-08 Novartis Ag Administracion oral de una calcitonina.
US8119693B2 (en) * 2007-05-08 2012-02-21 Sanford-Burnham Medical Research Institute Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CN101896201A (zh) * 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
WO2009083020A1 (en) * 2007-12-28 2009-07-09 F. Hoffmann-La Roche Ag Assessment of physiological conditions
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
CA2738583A1 (en) * 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
KR20110084455A (ko) 2008-11-13 2011-07-22 엑셀리시스, 인코포레이티드 퀴놀린 유도체를 제조하는 방법
WO2010065838A1 (en) 2008-12-04 2010-06-10 Exelixis, Inc. Methods of preparing quinoline derivatives
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
CA2768370A1 (en) 2009-07-17 2011-01-20 Exelixis, Inc. Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MX2012010506A (es) 2010-03-12 2012-10-15 Exelixis Inc Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida.
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
CN106420743A (zh) 2010-07-16 2017-02-22 埃克塞里艾克西斯公司 C‑met调节剂药物组合物
EP2593091A1 (en) 2010-07-16 2013-05-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
US20120089541A1 (en) * 2010-08-31 2012-04-12 Genentech, Inc. Biomarkers and methods of treatment
AU2011307306A1 (en) 2010-09-27 2013-05-02 Exelixis, Inc. Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012044572A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
EP2621483A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EP2643001A4 (en) 2010-11-22 2014-02-19 Glaxosmithkline Ip Dev Ltd METHOD OF TREATING CANCER
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
BR112014006702A2 (pt) 2011-09-22 2017-06-13 Exelixis Inc método para tratar osteoporose
CA2852771C (en) 2011-10-20 2019-11-26 Exelixis, Inc. Process for preparing quinoline derivatives
TW201818937A (zh) 2011-11-08 2018-06-01 美商艾克塞里克斯公司 治療癌症之方法
US20140330170A1 (en) 2011-11-08 2014-11-06 Exelixis, Inc. Method of Quantifying Cancer Treatment
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
CN114129566A (zh) 2012-09-07 2022-03-04 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂

Also Published As

Publication number Publication date
EP2758057B1 (en) 2017-05-31
NZ622722A (en) 2016-09-30
CN103957915A (zh) 2014-07-30
JP2014527984A (ja) 2014-10-23
EA201490676A1 (ru) 2015-02-27
JP6240075B2 (ja) 2017-11-29
US20140228401A1 (en) 2014-08-14
AU2012312364A1 (en) 2014-04-10
AR087995A1 (es) 2014-04-30
HK1201040A1 (en) 2015-08-21
BR112014006702A2 (pt) 2017-06-13
KR20140069133A (ko) 2014-06-09
IL231495B (en) 2019-03-31
US10166225B2 (en) 2019-01-01
ZA201401728B (en) 2016-01-27
TWI564009B (zh) 2017-01-01
IL231495A0 (en) 2014-04-30
GEP201606523B (en) 2016-08-10
EP3275443A1 (en) 2018-01-31
CA2848512A1 (en) 2013-03-28
ES2639093T3 (es) 2017-10-25
MX2014003027A (es) 2014-10-24
WO2013043840A1 (en) 2013-03-28
EP2758057A1 (en) 2014-07-30
AU2012312364B2 (en) 2017-11-09
UA115866C2 (uk) 2018-01-10
TW201313232A (zh) 2013-04-01

Similar Documents

Publication Publication Date Title
MX351133B (es) Metodo para tratar osteoporosis.
PH12017502141A1 (en) Compounds and their methods of use
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
MY182590A (en) Benzylamine derivatives
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
NZ708928A (en) Mannose derivatives for treating bacterial infections
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
TN2013000362A1 (en) Benzodioxane inhibitors of leukotriene production
MX2015007916A (es) Peri-carbinoles.
MX340190B (es) Compuestos para tratar infecciones por virus sincitial respiratorio.
TN2014000058A1 (en) A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes
MX355325B (es) Quinazolincarboxamida azetidinas.
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
PH12014502065A1 (en) Vesicular formulations
WO2013162981A3 (en) Breast implant spacers for the treatment of periprosthetic breast implant infections
PH12015501492A1 (en) Benzylamine derivatives
MX2015007460A (es) Agentes para el tratamiento del dolor y usos de los mismos.
EA201590014A1 (ru) Азетидиновые и пиперидиновые соединения, подходящие для применения в качестве ингибиторов pde10
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.

Legal Events

Date Code Title Description
FG Grant or registration